Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupert W Leong

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2015
Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to AustraliaYanna Ko, Viraj Kariyawasam, Mohamad Karnib, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
The American Journal of Gastroenterology|December 14, 2023
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance StudyWaqqas Afif, Ramesh P Arasaradnam, Maria T Abreu, et al.
Intestinal Research|August 10, 2018
The association between new generation oral contraceptive pill and the development of inflammatory bowel diseasesSantosh Sanagapalli, Yanna Ko, Viraj Kariyawasam, et al.
Inflammatory Bowel Diseases|December 22, 2023
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated DiseaseAkhilesh Swaminathan, James M Fulforth, Chris M Frampton, et al.
Journal of Crohn'S & Colitis|March 3, 2022
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionMaria T Abreu, David S Rowbotham, Silvio Danese, et al.
Gut|March 6, 2023
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatmentsEva Zhang, Thi H O Nguyen, Lilith F Allen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled TrialAviv Pudipeddi, Sudarshan Paramsothy, Viraj Kariyawasam, et al.
Inflammatory Bowel Diseases|January 1, 2019
Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel DiseaseViraj C Kariyawasam, Shin Kim, Fadi H Mourad, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2020
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapyRemo Panaccione, Silvio Danese, William J Sandborn, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2015
Inflammatory Bowel Disease Environmental Risk Factors: A Population-Based Case-Control Study of Middle Eastern Migration to AustraliaYanna Ko, Viraj Kariyawasam, Mohamad Karnib, et al.
Gut|December 17, 2017
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)Silvio Danese, Séverine Vermeire, Paul Hellstern, et al.
The American Journal of Gastroenterology|December 14, 2023
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance StudyWaqqas Afif, Ramesh P Arasaradnam, Maria T Abreu, et al.
Intestinal Research|August 10, 2018
The association between new generation oral contraceptive pill and the development of inflammatory bowel diseasesSantosh Sanagapalli, Yanna Ko, Viraj Kariyawasam, et al.
Inflammatory Bowel Diseases|December 22, 2023
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated DiseaseAkhilesh Swaminathan, James M Fulforth, Chris M Frampton, et al.
Journal of Crohn'S & Colitis|March 3, 2022
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term ExtensionMaria T Abreu, David S Rowbotham, Silvio Danese, et al.
Gut|March 6, 2023
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatmentsEva Zhang, Thi H O Nguyen, Lilith F Allen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 10, 2024
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled TrialAviv Pudipeddi, Sudarshan Paramsothy, Viraj Kariyawasam, et al.
Inflammatory Bowel Diseases|January 1, 2019
Comorbidities Rather Than Age Are Associated With the Use of Immunomodulators in Elderly-onset Inflammatory Bowel DiseaseViraj C Kariyawasam, Shin Kim, Fadi H Mourad, et al.
Alimentary Pharmacology & Therapeutics|October 21, 2020
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapyRemo Panaccione, Silvio Danese, William J Sandborn, et al.
Pageof 16